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Background
Before initiating or changing antiretroviral therapy (ART),
treatment decisions should be guided by HIV resistance
testing. Expert- and data-based interpretation systems for
genotypic mutation patterns are different approaches to
evaluate levels of drug resistance. Various interpretation
systems have shown good correlation with virological
outcomes. However, they can lead to discordant resistance
classifications. To date, there are few prospective data on
whether various interpretation systems lead to different
treatment decisions.
Methods
Prospective study in HIV-patients (pts) requiring ART-
change due to virological failure and genotypic resistance
to ≤1 drug. The choice of the new regimen was a three-step
approach. The physician's first choice was based on the
local standard of care genotypic interpretation (SOC).
Thereafter, choice could be adapted according to the vir-
tual phenotype report (vircoType, VT). Final treatment
decision was made at the patient's visit. Drug activity
scores were calculated as genotypic sensitivity scores
(GSS) acc. to SOC-interpretation and as continuous phe-
notypic SS (cPSS) acc. to VT. For new drugs, scores were set
to 1 if interpretation was not available (e.g. RAL, MVC).
Summary of results
N = 44 pts were included. Resistance to drugs of 3, 2 or 1
class was detected in 25%, 57%, and 18%, respectively. Of
N = 44 VT-based choices, 23 (52%) were different from
SOC-based choices. Differences were related to ≤2 drug
classes in 12, to only PI or NRTI in 11 pts. New drug
classes were foreseen in 11 SOC-choices and in 12 VT-
choices. 64% of VT-choices were identical to final choices
compared to only 39% of SOC-choices. For SOC-based
choices, mean GSS was 2.1, mean cPSS was 2.0. Mean
increase in cPSS from SOC-based to both VT- and final
choices, was 0.21. Regarding only pts with different VT-
and SOC-based choices, mean cPSS-increase was 0.40 (p
< 0.05) with no further increase if final choice was again
different. Mean number of drugs did not differ for SOC-
and VT-choices (3.4), but was slightly higher for final reg-
imens (3.6). Mean cPSS per drug was 0.61 for SOC-
choices, 0.67 for VT-choices and 0.64 for final regimens.
Conclusion
The use of calculated phenotypic information (VT)
derived from genotypic mutation patterns led to revised
treatment decisions in more than 50% of HIV pts. New
treatment choices mostly consisted in different use of
NRTI and PI. There was a trend to higher activity scores in
the revised treatment choices.
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